UMIN-CTR History

Name：　　UMIN ID：


Unique ID issued by UMIN UMIN000016553
Receipt number R000019185
Scientific Title Phase 2 study of bevacizumab beyond progression disease for glioblastoma treated with key therapeutics.
Date of disclosure of the study information 2015/02/28
Last modified on 2023/01/17 08:37:23

No. Disposal Last modified on Item of update
1 Insert 2015/02/16 19:29:14
2 Update 2015/04/02 18:03:32 Recruitment status
3 Update 2015/04/17 15:05:26 Other related information
4 Update 2015/04/17 15:10:17


Key inclusion criteria
Key inclusion criteria
5 Update 2016/02/22 15:41:12 Key exclusion criteria
Key exclusion criteria
6 Update 2016/02/22 16:06:54 Other related information
7 Update 2016/02/22 16:19:19 Other related information
Other related information
8 Update 2017/02/16 12:29:45 Recruitment status
9 Update 2017/08/18 13:53:39 Name of primary person or sponsor
Organization
Organization
10 Update 2017/08/18 13:57:29 Other related information
11 Update 2019/02/19 13:11:16 Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
12 Update 2019/08/20 12:26:00 Number of participants that the trial has enrolled
13 Update 2020/08/20 09:32:41 Recruitment status
Date of IRB
14 Update 2020/08/20 09:38:34 1st name of lead principal investigator
Last name of lead principal investigator
1st name of lead principal investigator
Last name of lead principal investigator
Zip code
Address

Last name of contact person

Last name of contact person
Zip code
Address
Organization
Organization
Address
Address
Tel
Email
15 Update 2020/08/20 10:34:58 Recruitment status
16 Update 2022/12/07 10:35:10 Recruitment status
17 Update 2022/12/07 10:47:50 URL releasing protocol
Publication of results
URL related to results and publications
Results
Results
Results date posted
Baseline Characteristics
Baseline Characteristics
Participant flow
Participant flow
Adverse events
Adverse events
Outcome measures
Outcome measures
18 Update 2022/12/07 10:52:42 Anticipated trial start date
Last follow-up date
19 Update 2023/01/16 14:34:03 Outcome measures
20 Update 2023/01/17 08:19:29 Results
Date of the first journal publication of results
Baseline Characteristics
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
21 Update 2023/01/17 08:37:23 Institutions